Monitoring P-waves to detect degradation of atrial myocardium

• US 7,620,446 B2
• Filed: 07/31/2003
• Issued: 11/17/2009
• Est. Priority Date: 07/31/2003
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Ferek-Petric, Bozidar
• Primary Examiner(s): Manuel; George
• Assistant Examiner(s): Flory; Christopher A
• Application Number:
  US10/631,614
• Publication Number:
  US 20050027321A1
• Time in Patent Office: 2,301 Days
• Field of Search: 607 27- 29, 600509-510
• US Class Current: 600/509
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/353 Detecting P-waves

Abstract

An implantable medical device (IMD) monitors at least one characteristic of P-waves within an electrogram signal. By monitoring changes in the characteristic over time, the IMD detects degradation of the atrial myocardium. In some embodiments, the IMD detects ischemia, an increased probability of the occurrence of angina, or a risk of future atrial fibrillation based on changes in the characteristic over time. The IMD can include a memory to store information relating to the detection and other diagnostic information for retrieval and evaluation by a clinician, and/or an alarm to alert the patient of the detection. In some embodiments, the IMD switches out of an atrial-tracking ventricular pacing mode, decreases the maximum tracking rate for an atrial-tracking ventricular pacing mode, increases the aggressiveness of rate-responsive atrial pacing, and/or initiates or modifies delivery of a therapy, such as a drug or neurostimulation, in response to the identification.

Claims

1. A method of monitoring electrical activity of a heart, comprising:

receiving a signal that represents electrical activity within the heart of a patient via electrodes;

processing the signal to monitor dispersions of widths of P-waves;

determining whether increases in the monitored dispersions are one of long term increases and short term increases; and

distinguishing between medically significant changes in the heart based upon the determining whether increases in the monitored dispersions are one of long term increases and short term increases and providing an indication thereof.

2. The method of claim 1, wherein processing the signal to monitor dispersions comprises:

determining first dispersions for a first subset of P-waves and second dispersions for a second subset of the P-waves; and

comparing the first and second dispersions.

3. The method of claim 1, wherein processing the signal to monitor dispersions comprises:

measuring one of differences between current and previous dispersions and a ratio of current and previous dispersions; and

comparing the measured one of differences between current and previous dispersions and a ratio of current and previous dispersions to a template stored in a memory.

4. The method of claim 1, wherein distinguishing between medically significant changes comprises detecting degradation of an atrial myocardium in response to the increases being determined to be long term, and identifying impending angina in response to the increases being determined to be short term.

5. The method of claim 4, further comprising confirming the detecting of impending angina, wherein the confirming comprises determining one of whether shortening of QT intervals has occurred and whether an activity level has increased.

6. The method of claim 1, further comprising:

storing the indication of the medically significant change in the heart within a memory; and

providing the indication of the medically significant change in the heart to a user via a programming device upon interrogation by the programming device.

7. The method of claim 1, further comprising activating an alarm based on the indication of the medically significant change in the heart.

8. The method of claim 1, further comprising controlling delivery of therapy to the patient based on the indication of the medically significant change in the heart.

9. The method of claim 8, wherein controlling delivery of therapy comprises one of switching from an atrial-tracking pacing mode to a VVI pacing mode based on the dispersions, decreasing a maximum tracking rate for an atrial-tracking pacing mode based on the indication of the medically significant change in the heart, increasing aggressiveness of rate responsive atrial pacing based on the indication of the medically significant change in the heart, controlling delivery of a drug by a drug delivery device based on the indication of the medically significant change in the heart and controlling delivery of neurostimulation based on the indication of the medically significant change in the heart.

10. The method of claim 1, wherein processing the signal to monitor dispersions of widths of P-waves comprises:

calculating a dispersion for a current period of time having a predetermined length; and

comparing the dispersion calculated for the current period of time to a dispersion calculated a predetermined time prior to the current period of time, wherein the predetermined length of the current period of time and the predetermined time prior to the current period of time vary in response to the indication of the medically significant change in the heart.

11. An implantable medical device comprising:

electrodes to detect a signal that represents electrical activity within a heart of a patient; and

a processor to monitor dispersions of widths of P-waves, determine whether increases in the monitored dispersions are one of long term increases and short term increases, and distinguish between medically significant changes in the heart based upon the determination whether increases in the monitored dispersions are one of long term increases and short term increases and provide an indication thereof.

12. The device of claim 11, wherein the processor determines first dispersions for a first subset of P-waves and second dispersions for a second subset of the P-waves, and compares the first and second dispersions.

13. The device of claim 11, wherein the processor measures one of differences between current and previous dispersions and a ratio of current and previous dispersions and compares the measured one of differences between current and previous dispersions and a ratio of current and previous dispersions to a template stored in a memory.

14. The device of claim 11, wherein the processor detects degradation of an atrial myocardium in response to the increases being determined to be long term and detects impending angina in response to the increases being determined to be short term.

15. The device of claim 14, wherein the processor determines, in response to impending angina being identified, one of whether shortening of QT intervals has occurred and whether an activity level has increased to confirm the identifying of impending angina.

16. The device of claim 11, further comprising:

a memory; and

a telemetry circuit, wherein the processor stores the indication of the medically significant change in the heart within the memory, and provides the indication of the medically significant change in the heart to a user via the telemetry circuit and a programming device upon interrogation by the programming device.

17. The device of claim 11, further comprising an alarm, wherein the processor activates the alarm based on the distinguishing.

18. The device of claim 11, wherein the processor performs one of controlling delivery of pacing pulses to a ventricle of the heart and switching from an atrial-tracking pacing mode to a VVI pacing mode based on the indication of the medically significant change in the heart, controlling delivery of pacing pulses to a ventricle of the heart and decreasing a maximum tracking rate for an atrial-tracking pacing mode based on the indication of the medically significant change in the heart, controlling delivery of pacing pulses to an atrium of the heart and increasing aggressiveness of rate responsive atrial pacing based on the indication of the medically significant chance in the heart, controlling delivery of a drug by a drug delivery device based on the indication of the medically significant change in the heart, and controlling delivery of neurostimulation based on the indication of the medically significant change in the heart.

19. The device of claim 11, wherein the monitoring of dispersions of widths of P-waves by the processor comprises:

calculating a dispersion for a current period of time having a predetermined length; and

comparing the dispersion calculated for the current period of time to a dispersion calculated a predetermined time prior to the current period of time, wherein the predetermined length of the current period of time and the predetermined time prior to the current period of time vary in response to the indication of the medically significant chance in the heart.

20. A computer-readable medium having computer-executable instructions for performing a method, comprising:

monitoring dispersions of widths of P-waves within a signal that represents electrical activity within a heart of a patient;

determining whether increases in the monitored dispersions are one of long term increases and short term increases; and

distinguishing between medically significant changes in the heart based upon the determining whether increases in the monitored dispersions are one of long term increases and short term increases and providing an indication thereof.

21. The computer-readable medium of claim 20, wherein the monitoring comprises:

determining first dispersions for a first subset of P-waves and second dispersions for a second subset of the P-waves; and

comparing the first and second dispersions.

22. The computer-readable medium of claim 20, wherein the monitoring comprises:

measuring one of differences between current and previous dispersions and a ratio of current and previous dispersions; and

comparing the measured one of differences between current and previous dispersions and a ratio of current and previous dispersions to a template stored in a memory.

23. The computer-readable medium of claim 20, wherein distinguishing between medically significant changes comprises detecting degradation of an atrial myocardium in response to the increases being determined to be long term, and detecting an increased probability of an occurrence of angina in response to the increases being determined to be short term.

24. The computer readable medium of claim 23, further comprising confirming the detecting of an increased probability of an occurrence of angina, wherein the confirming comprises determining one of whether shortening of QT intervals has occurred and whether an activity level has increased.

25. The computer-readable medium of claim 20, further comprising controlling delivery of therapy to the patient based on the indication of the medically significant change in the heart.

26. The computer-readable medium of claim 25, wherein controlling delivery of therapy includes one of switching from an atrial-tracking pacing mode to a VVI pacing mode based on the indication of the medically significant change in the heart, decreasing a maximum tracking rate for atrial-tracking pacing mode based on the indication of the medically significant change in the heart, increasing aggressiveness of rate responsive atrial pacing based on the indication of the medically significant change in the heart, controlling delivery of a drug by a drug delivery device based on the indication of the medically significant change in the heart, and controlling delivery of neurostimulation based on the indication of the medically significant change in the heart.

27. The computer readable medium of claim 20, wherein monitoring dispersions of widths of P-waves comprises:

calculating a dispersion for a current period of time having a predetermined length; and

comparing the dispersion calculated for the current period of time to a dispersion calculated a predetermined time prior to the current period of time, wherein the predetermined length of the current period of time and the predetermined time prior to the current period of time vary in response to the indication of the medically significant change in the heart.

28. An implantable medical device system comprising:

a therapy delivery device to deliver a therapy to a patient; and

a monitoring device to monitor dispersions of widths of P-waves, determine whether increases in the monitored dispersions are one of long term increases and short term increases, and distinguish between medically significant changes in the heart based upon the determination whether increases in the monitored dispersions are one of long term increases and short term increases and provide an indication thereof, and control delivery of therapy by the therapy delivery device based on the indication of the medically significant change in the heart by the monitoring device.

29. The system of claim 28, wherein the therapy delivery device is a drug delivery device, and the monitoring device controls delivery of a drug by the drug delivery device based on the indication of the medically significant change in the heart.

30. The system of claim 29, wherein the therapy delivery device is a neurostimulator, and the monitoring device controls delivery of neurostimulation by the neurostimulator based on the indication of the medically significant change in the heart.

31. The system of claim 28, wherein the monitoring of dispersions of widths of P-waves by the monitoring device comprises:

calculating a dispersion for a current period of time having a predetermined length; and

comparing the dispersion calculated for the current period of time to a dispersion calculated a predetermined time prior to the current period of time, wherein the predetermined length of the current period of time and the predetermined time prior to the current period of time vary in response to the indication of the medically significant change in the heart.

32. The system of claim 28, wherein the monitoring device detects degradation of an atrial myocardium in response to the increases being determined to be long term, detects impending angina in response to the increases being determined to be short term, and confirms the detecting of impending angina, wherein the confirming comprises determining one of whether shortening of QT intervals has occurred and whether an activity level has increased.